IntellAif

Pharmaceutical companies face significant drop out rates of their lead candidates due to a lack of efficacy. Our solution directly addresses a critical challenge in drug development journey by de-risking clinical trials through novel, true AI-driven insights derived from the preclinical stage. This is an angle presently not used in AI drug discovery related verticals and represents a gap in the market. At IntellAif, we are developing an AI-driven solution that enables the in silico assesment of the preclinical data package, optimizing for successful clinical trials at an early stage. Our technology aims to de-risk drug development by enhancing the translational accuracy of preclinical models. The product is a SaaS type platform with our proprietary models accessed, stratified by selected preclinical models. With the incorporation of LLMs and cloud computing power we believe it is a powerful platform to provide the user a research companion to extract insights from preclinical investigations to perform go/no-go analysis on lead candidates.